Day: December 11, 2023

Peter BordesCollective Audience Appoints Technology Visionary, Investor, and Executive Leader, Peter Bordes, as Chief Executive OfficerNEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) — Collective Audience, Inc. (Nasdaq: CAUD), a leading innovator of audience based performance advertising and media solutions, has appointed Peter Bordes as chief executive officer, succeeding Brent Suen who will continue to serve on the board of directors.A lifelong entrepreneur, operator and venture investor, Bordes brings to the company more than 30 years of executive and board experience leading private and public companies across the AdTech, media, AI, fintech and technology sectors. His career and investing have focused on innovation and disruptive technologies that drive digital transformation. “I have followed Peter’s career since the early...

PEKIN, Ill., Dec. 11, 2023 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols and essential ingredients, has published its inaugural Sustainability Summary outlining the company’s performance in key areas, such as environmental, health and safety, along with the strategy and vision for advancements in sustainability, responsible sourcing, and risk management. “As a renewables company, we are dedicated to implementing sustainable best practices that are good for our business, our stakeholders and our planet,” said Bryon McGregor, President and CEO of Alto Ingredients. “From integrating innovative practices at our facilities that ensure optimal efficiency, contributing to a lower carbon footprint with our ethanol fuel, and to giving back to the community through...

KH Group PlcPress Release 11 December 2023 at 3:30 pm EET KH Group’s has made follow-on investment in Indoor KH Group together with other shareholders of Indoor Group Holding Oy (“Indoor”) have made combined EUR 2.8 million follow-on investments in Indoor. These follow-on investments were made by subordinated loan. Loan proceeds are used to repay interest-bearing debts. The follow-on investments strengthen Indoor’s balance sheet accordingly. KH Group Plc’s share of the subordinated loan in Indoor is EUR 2.1 million. This arrangement has been finalised today and will not affect the ownership structure in Indoor Group Holding Oy. KH GROUP PLC FURTHER INFORMATION: CEO Lauri Veijalainen, puh. +358 46 876 1648 DISTRIBUTION: Major mediawww.khgroup.com Sievi Capital is now a conglomerate with a new name KH Group. Our four business areas are...

Marcus Lemonis will serve as the Chairman of the Board MIDVALE, Utah, Dec. 11, 2023 (GLOBE NEWSWIRE) — Beyond, Inc., (NYSE: BYON) (“Beyond” or the “Company”), the parent company of online furniture and home furnishings retailer Bed Bath & Beyond, formerly known as Overstock, today announced that, on December 10, 2023, Allison H. Abraham notified the Board of Directors of Beyond (“the Board”) of her decision to retire. As part of that transition, Ms. Abraham resigned as a Director of the Company, effective immediately. Marcus Lemonis will transition to the role of Chairman of the Company’s Board of Directors. Ms. Abraham said, “I thank the Board, management, and rest of the Beyond family for their support over the years. It has been an honor to work for the Company and represent our shareholders for more than two decades....

– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adult patients with hypoparathyroidism. The agency considered the resubmission a complete, class 2 response and set a Prescription Drug User Fee Act (PDUFA) goal date of May 14, 2024. In the United States, TransCon PTH (palopegteriparatide) is an investigational prodrug of parathyroid hormone (PTH [1-34]) for adult patients with hypoparathyroidism. “We are pleased that the FDA can continue its review of TransCon PTH and look forward to working with the agency during its review,” said Jan Mikkelsen, President...

– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI monotherapy also recommended as the only preferred regimen in subsequent lines of therapy – -– LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy– REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) announced today that the National Comprehensive Cancer Network (NCCN) has updated the clinical practice guidelines for nasopharyngeal carcinoma (NPC) to include LOQTORZI™ (toripalimab-tpzi) as a preferred, category 1 first-line treatment option for adults with metastatic or recurrent locally advanced NPC...

Glen Rock, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a biopharmaceutical company focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, on December 6, 2023, it has entered into an agreement with Ponto Ventures LLC providing for Will Clodfelter to serve as RespireRx’s Senior Vice President of Business Development on a part-time basis. Mr. Clodfelter will initially lead the business development efforts with respect to dronabinol, the lead asset of ResolutionRx Ltd, a wholly-owned Australian subsidiary of the Company. Mr. Clodfelter will collaborate with Jeff Eliot Margolis, the Company’s Senior Vice President, Chief Financial Officer,...